tetano
Editor, Senior Moderator
Br J Haematol
. 2023 Mar 9.
doi: 10.1111/bjh.18714. Online ahead of print.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial
Sian E Faustini[SUP] 1 [/SUP], Andrew Hall[SUP] 2 [/SUP], Sarah Brown[SUP] 2 [/SUP], Sadie Roberts[SUP] 2 [/SUP], Harriet Hill[SUP] 3 [/SUP], Zania Stamataki[SUP] 3 [/SUP]; (PITCH) consortium[SUP] 4 [/SUP]; Matthew W Jenner[SUP] 5 [/SUP], Roger G Owen[SUP] 6 [/SUP], Guy Pratt[SUP] 7 [/SUP], Gordon Cook[SUP] 2 6 [/SUP], Alex Richter[SUP] 1 [/SUP], Mark T Drayson[SUP] 1 [/SUP], Martin F Kaiser[SUP] 8 9 [/SUP], Jennifer L J Heaney[SUP] 1 [/SUP]
Affiliations
Abstract
Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.
Keywords: anti-CD38; antibodies; high-dose therapy; multiple myeloma; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
. 2023 Mar 9.
doi: 10.1111/bjh.18714. Online ahead of print.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial
Sian E Faustini[SUP] 1 [/SUP], Andrew Hall[SUP] 2 [/SUP], Sarah Brown[SUP] 2 [/SUP], Sadie Roberts[SUP] 2 [/SUP], Harriet Hill[SUP] 3 [/SUP], Zania Stamataki[SUP] 3 [/SUP]; (PITCH) consortium[SUP] 4 [/SUP]; Matthew W Jenner[SUP] 5 [/SUP], Roger G Owen[SUP] 6 [/SUP], Guy Pratt[SUP] 7 [/SUP], Gordon Cook[SUP] 2 6 [/SUP], Alex Richter[SUP] 1 [/SUP], Mark T Drayson[SUP] 1 [/SUP], Martin F Kaiser[SUP] 8 9 [/SUP], Jennifer L J Heaney[SUP] 1 [/SUP]
Affiliations
- PMID: 36895158
- DOI: 10.1111/bjh.18714
Abstract
Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.
Keywords: anti-CD38; antibodies; high-dose therapy; multiple myeloma; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).